KR20240030727A - Furyl thiazole compound and composition for preventing or treating sarcopenia comprising the same as an active ingredient - Google Patents

Abstract

The present invention relates to a composition for preventing or treating sarcopenia containing a furylthiazole-based compound represented by Formula 1 as an active ingredient, and it was confirmed that the furylthiazole-based compound exhibits an effect of improving atrophy of root canals formed in myoblasts. By doing so, it can be usefully used as a composition for preventing, treating, or improving sarcopenia.

Description

Furyl thiazole compound and composition for preventing or treating sarcopenia comprising the same as an active ingredient {Furyl thiazole compound and composition for preventing or treating sarcopenia comprising the same as an active ingredient}

The present invention relates to a furylthiazole-based compound and a composition for preventing or treating sarcopenia containing the same as an active ingredient.

Sarcopenia, which is caused by degeneration of spinal nerves, motor nerves, or skeletal muscle fibers, is one of the representative incurable diseases whose cause has not yet been identified. According to research so far, the motor nerves that induce skeletal muscle contraction degenerate and skeletal muscle contraction does not proceed, or the expression of proteins involved in muscle contraction within skeletal muscles is reduced (sarcopenia), or the proteins are modified. It is known that normal skeletal muscle contraction does not proceed, and in the long term, the motor nerves or skeletal muscles are transformed into fibrous tissue.

Among sarcopenia, degenerative sarcopenia (sarcopenia) is defined as an age-related decrease in muscle mass, and is increasingly recognized as having a significant impact on quality of life in old age. Degenerative sarcopenia occurs in 13-24% of people under 70 years of age, but occurs in more than 50% of people over 80 years of age. Muscle weakness associated with muscle loss causes fatigue, reduced work performance, and risk of fractures such as femur fractures. It is known to be related to the increase in Patients suffering from sarcopenia have skeletal muscle indices below the standard value and experience difficulties in daily life, such as decreased grip strength and walking speed. In terms of body composition, while the amount of muscle is clearly lost, body fat tends to increase.

Nutritional approaches and exercise training methods are being studied as treatments for sarcopenia. Treatment using protein compounds such as appetite stimulants and testosterone has been proposed, but the treatment effect is not satisfactory. Exercise training is difficult to consider as an appropriate alternative because it is often difficult for elderly people with sarcopenia to even attempt exercise. Pharmaceutical methods to slow the progression of sarcopenia are mainly used to suppress muscular atrophy, a type of sarcopenia, caused by degeneration or progressive mutation of muscle cells.

Republic of Korea Patent No. 10-1944985 (published on January 9, 2019)

In order to solve the above problems, the purpose of the present invention is to provide a new pharmaceutical composition that can prevent, treat or improve sarcopenia, and the furylthiazole-based compound has the effect of improving atrophy of root canals formed in myoblasts. By confirming this, the furylthiazole-based compound is provided as a new drug for preventing, treating, or improving sarcopenia.

The present invention provides a pharmaceutical composition for preventing or treating sarcopenia comprising a furylthiazole-based compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.

[Formula 1]

In addition, the present invention provides a health functional food composition for preventing or improving sarcopenia containing the furylthiazole-based compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

In addition, the present invention provides a method of treating sarcopenia comprising administering the pharmaceutical composition in a pharmaceutically effective amount to an individual suffering from sarcopenia.

According to the present invention, as it was confirmed that the furylthiazole-based compound represented by Formula 1 improves atrophy of root canals formed in myoblasts, it can be usefully used as a composition for preventing, treating, or improving sarcopenia.

Figure 1 shows the results of staining MYH (Myosin heavy chain) and nuclei by ICC (Immunocytochemistry) to evaluate the effect of the furylthiazole compound represented by Formula 1 on the myotube formation process of myoblasts.
Figure 2 shows the myotube area, myotube diameter, and fusion index to evaluate the effect of the furylthiazole compound represented by Formula 1 on the myotube formation process of myoblasts. This is the result of evaluating.

The terms used in this specification are general terms that are currently widely used as much as possible while considering the function in the present invention, but this may vary depending on the intention or precedent of a person skilled in the art, the emergence of new technology, etc. In addition, in certain cases, there are terms arbitrarily selected by the applicant, and in this case, the meaning will be described in detail in the description of the relevant invention. Therefore, the terms used in the present invention should be defined based on the meaning of the term and the overall content of the present invention, rather than simply the name of the term.

Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by a person of ordinary skill in the technical field to which the present invention pertains. Terms defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related technology, and unless clearly defined in the present application, should not be interpreted in an ideal or excessively formal sense. No.

The numerical range includes the values defined in the range above. Every maximum numerical limit given throughout this specification includes all lower numerical limits as if the lower numerical limit were explicitly written out. Every minimum numerical limit given throughout this specification includes every higher numerical limit as if such higher numerical limit was clearly written. All numerical limits given throughout this specification will include all better numerical ranges within the broader numerical range, as if the narrower numerical limits were clearly written.

Hereinafter, the present invention will be described in more detail.

The present invention provides a pharmaceutical composition for preventing or treating sarcopenia comprising a furylthiazole-based compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.

[Formula 1]

The furylthiazole-based compound represented by Formula 1 has the IUPAC name 4-[(dibenzo[b,d]furan-2-yloxy)methyl]-2-(2-furyl)-1,3-thiazole (4 It is a compound called -[(Dibenzo[b,d]furan-2-yloxy)methyl]-2-(2-furyl)-1,3-thiazole).

The furylthiazole compound represented by Formula 1 or a pharmaceutically acceptable salt thereof may cause one or more sarcopenia symptoms selected from the group consisting of decreased body weight, skeletal muscle weight, grip strength, and expression levels of muscle protein-related genes due to sarcopenia. It can be improved, but it is not limited to this.

The muscle protein-related genes include genes producing muscle proteins, which are genes encoding MyoD or Myogenin; Alternatively, it may be a gene that destroys a muscle protein, such as a gene encoding Myostatin, Atrogin-1, or MuRF1 (Muscle RING-finger protein-1), but is not limited thereto.

In addition, the furylthiazole-based compound represented by Formula 1 or a pharmaceutically acceptable salt thereof can improve root canal atrophy.

The sarcopenia includes degenerative muscle weakness or muscular dystrophy. The sarcopenia may be degenerative sarcopenia, and refers to a decrease in muscle mass of skeletal muscles due to a decrease in the number and cross-sectional area of muscle fibers due to various reasons such as aging. The muscular atrophy refers to a disease in which muscles atrophy. Specifically, it is a disease in which the muscles of the extremities gradually atrophy almost symmetrically, and may include amyotrophic lateral sclerosis or spinal progressive muscular atrophy.

In the present invention, the pharmaceutically acceptable salt consists of sodium salt, potassium salt, calcium salt, lithium salt, magnesium salt, cesium salt, aminium salt, ammonium salt, triethylaminium salt, and pyridinium salt. It may be one or more basic salts selected from the group, but is not limited thereto.

In addition, the pharmaceutically acceptable salts include hydrochloric acid, hydrobromic acid, sulfuric acid, sulfurous acid, phosphoric acid, citric acid, acetic acid, maleic acid, fumaric acid, glucolic acid, methanesulfonic acid, benzenesulfonic acid, camphorsulfonic acid, oxalic acid, and malonic acid. , glutaric acid, acetic acid, glycolic acid, succinic acid, tartaric acid, 4-toluenesulfonic acid, galacturonic acid, embonic acid, glutamic acid, citric acid, and aspartic acid. It is not limited.

The pharmaceutical composition according to the present invention can be manufactured in unit dose form by formulating using a pharmaceutically acceptable carrier according to a method that can be easily performed by those skilled in the art, or by placing it in a multi-dose container. there is.

The pharmaceutically acceptable carriers are those commonly used in preparation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, Includes, but is not limited to, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, etc. In addition to the above components, the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc.

In the present invention, the content of additives included in the pharmaceutical composition is not particularly limited and can be appropriately adjusted within the content range used in conventional formulations.

The pharmaceutical compositions include injectable formulations such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, tablets, creams, gels, patches, sprays, ointments, warning agents, lotions, liniment agents, paste agents, and cataplasmase agents. It may be formulated in the form of one or more external preparations selected from the group consisting of.

The pharmaceutical composition of the present invention may additionally contain pharmaceutically acceptable carriers and diluents for formulation. The pharmaceutically acceptable carriers and diluents include excipients such as starch, sugar, and mannitol, fillers and extenders such as calcium phosphate, cellulose derivatives such as carboxymethylcellulose, hydroxypropylcellulose, gelatin, alginate, and polyvinyl pyrrolidone. It includes, but is not limited to, binders such as copper, lubricants such as talc, calcium stearate, hydrogenated castor oil and polyethylene glycol, disintegrants such as povidone and crospovidone, and surfactants such as polysorbate, cetyl alcohol, glycerol, etc. The pharmaceutically acceptable carrier and diluent may be biologically and physiologically friendly to the subject. Examples of diluents include, but are not limited to, saline, aqueous buffers, solvents, and/or dispersion media.

The pharmaceutical composition of the present invention can be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally, or topically) depending on the desired method. For oral administration, it can be formulated as tablets, troches, lozenges, aqueous suspensions, oily suspensions, powders, granules, emulsions, hard capsules, soft capsules, syrups, elixirs, etc. In the case of parenteral administration, it can be formulated as an injection, suppository, powder for respiratory inhalation, aerosol for spray, ointment, powder for application, oil, cream, etc.

The dosage of the pharmaceutical composition of the present invention is determined by the patient's condition and weight, age, gender, health, dietary constitution specificity, nature of the preparation, degree of disease, administration time of the composition, administration method, administration period or interval, excretion rate, and The range may vary depending on the drug form and can be appropriately selected by a person skilled in the art. For example, it may range from about 0.1 to 10,000 mg/kg, but is not limited and may be administered once to several times a day.

The pharmaceutical composition may be administered orally or parenterally (eg, intravenously, subcutaneously, intraperitoneally, or topically applied) depending on the desired method. The pharmaceutically effective amount and effective dosage of the pharmaceutical composition of the present invention may vary depending on the formulation method, administration method, administration time, and/or administration route of the pharmaceutical composition, and those skilled in the art will be able to determine the desired treatment. Effective dosage can be easily determined and prescribed. The pharmaceutical composition of the present invention may be administered once a day, or may be administered in several divided doses.

In addition, the present invention provides a health functional food composition for preventing or improving sarcopenia containing the furylthiazole-based compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

The present invention can be generally used with commonly used foods.

The food composition of the present invention can be used as a health functional food. The term “health functional food” refers to food manufactured and processed using raw materials or ingredients with functionality useful to the human body in accordance with the Health Functional Food Act, and “functional” refers to food that is related to the structure and function of the human body. It means ingestion for the purpose of controlling nutrients or obtaining useful health effects such as physiological effects.

The food composition of the present invention may contain common food additives, and its suitability as a “food additive” is determined in accordance with the general provisions and general test methods of the food additive code approved by the Ministry of Food and Drug Safety, unless otherwise specified. The decision is made based on the specifications and standards for the item.

Items listed in the "Food Additives Code" include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid; natural additives such as subchromic pigment, licorice extract, crystalline cellulose, high-liquid pigment, and guar gum; Examples include mixed preparations such as sodium L-glutamate preparations, noodle additive alkaline preparations, preservative preparations, and tar coloring preparations.

The food composition of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc.

For example, among health functional foods in the form of capsules, hard capsules can be manufactured by mixing and filling the composition according to the present invention with additives such as excipients in ordinary hard capsules, and soft capsules can be manufactured by mixing and filling the composition according to the present invention. It can be manufactured by mixing with additives such as excipients and filling it with a capsule base such as gelatin. The soft capsule may contain plasticizers such as glycerin or sorbitol, colorants, preservatives, etc., if necessary.

Definitions of terms such as excipients, binders, disintegrants, lubricants, coagulants, flavoring agents, etc. are described in literature known in the art and include those with the same or similar functions. There is no particular limitation on the type of food, and it includes all health functional foods in the conventional sense.

In the present invention, the term “prevention” refers to all actions that inhibit or delay sarcopenia by administering the composition according to the present invention.

In the present invention, the term “treatment” refers to any action that improves or beneficially changes sarcopenia by administering the composition according to the present invention.

In the present invention, the term “improvement” refers to all actions that improve the bad condition of sarcopenia by administering the composition according to the present invention.

In addition, the present invention provides a method of treating sarcopenia comprising administering the pharmaceutical composition in a pharmaceutically effective amount to an individual suffering from sarcopenia.

The pharmaceutically effective amount is an amount effective for the treatment of a disease, such as the amount of the composition administered to the subject to be treated, preventing recurrence, alleviating symptoms, inhibiting direct or indirect pathological results, It may include any amount of the composition that prevents metastasis, reduces the rate of progression, alleviates or temporarily alleviates the condition, or improves the prognosis.

Hereinafter, the present invention will be described in detail through examples to aid understanding. However, the following examples only illustrate the content of the present invention and the scope of the present invention is not limited to the following examples. Examples of the present invention are provided to more completely explain the present invention to those skilled in the art.

[Example 1] Confirmation of differentiation activity effect of myotube cells

In order to confirm the effectiveness of the furylthiazole compound represented by Formula 1 in treating sarcopenia, the effect of the furylthiazole compound represented by Formula 1 on the myotube formation process of myoblasts was evaluated. Furylthiazole-based compounds were obtained commercially. DMEM (Dulbecco's Modified Eagle's Medium) containing 1% penicillin/streptomycin and 10% FBS (Fetal Bovine Serum) was used as a growth medium, and 1% penicillin/streptomycin (penicillin/streptomycin) was used as a growth medium. DMEM (Dulbecco's Modified Eagle's Medium) containing streptomycin) and 2% NHS (Normal Horse Serum) was used as a differentiation medium. A 96-well plate was coated with 0.1% gelatin solution. C2C12 cells, a 4th passage mouse myoblast cell line, at a density of 50-60% were collected using trypsin, and 5000 cells were spread on a 96-well plate coated with gelatin along with growth medium. After culturing for 24 hours, the medium was replaced with differentiation medium, and cultured for 48 hours to induce myotube formation. Afterwards, the negative control and test groups were treated with 150 μM of dexamethasone to induce atrophy of the root canals. After 24 hours, the test group was treated with a furylthiazole compound represented by Formula 1 at a concentration of 5 to 25 μM, and the positive and negative control groups were treated with 0.1% DMSO. 24 hours later, MYH (Myosin heavy chain) and nuclei were stained using the ICC (Immunocytochemistry) method, and myotube area, myotube diameter, and fusion index were evaluated.

As shown in Figures 1, 2, and Table 1, in the negative control group, when the cells in which myotubes were formed were treated with dexamethasone, the myotubes were atrophied and the diameter of the tubes was reduced. Formula 1 When treated with a furylthiazole-based compound represented by , root canal atrophy was shown to improve as the treatment concentration increased. The above results demonstrate that the furylthiazole-based compound represented by Formula 1 improves the muscle loss phenomenon in root canals induced by dexamethasone, and the furylthiazole-based compound represented by Formula 1 reduces sarcopenia. This suggests that there is an effect that can be improved and treated.

Myotube area C+ C- 5μM 25μM mean 190614 115584 147452 169408 S.D. 7743 12322 6538 18899 C-test 0.01 0.00 Myotube diameter C+ C- 5μM 25μM mean 25 16 17 20 S.D. 3 2 3 2 C-test 0.05 0.03 Fusion index C+ C- 5μM 25μM mean 20 12 16 19 S.D. One One One 2 C-test 0.00 0.00

As the specific parts of the present invention have been described in detail above, it is clear to those skilled in the art that these specific techniques are merely preferred embodiments and do not limit the scope of the present invention. do. That is, the practical scope of the present invention is defined by the appended claims and their equivalents.

Claims (7)

A pharmaceutical composition for preventing or treating sarcopenia comprising a furylthiazole-based compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient:
[Formula 1]
The method of claim 1, wherein the furylthiazole-based compound or a pharmaceutically acceptable salt thereof is used to reduce one or more symptoms of sarcopenia selected from the group consisting of decreased body weight, skeletal muscle weight, grip strength, and expression levels of muscle protein-related genes due to sarcopenia. A pharmaceutical composition for preventing or treating sarcopenia, characterized in that it improves sarcopenia. The method according to claim 2, wherein the muscle protein-related gene is a gene that produces muscle protein, which is a gene encoding MyoD or Myogenin; Or, preventing or treating sarcopenia, characterized in that it is a gene that destroys muscle protein, which is a gene encoding Myostatin, Atrogin-1, or MuRF1 (Muscle RING-finger protein-1). For pharmaceutical compositions. The pharmaceutical composition for preventing or treating sarcopenia according to claim 1, wherein the furylthiazole-based compound or a pharmaceutically acceptable salt thereof has the effect of improving root canal atrophy. The pharmaceutical composition for preventing or treating sarcopenia according to claim 1, wherein the sarcopenia is degenerative muscle weakness or muscular atrophy. A health functional food composition for preventing or improving sarcopenia comprising a furylthiazole compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient:
[Formula 1]
A method of treating sarcopenia comprising administering the pharmaceutical composition of any one of claims 1 to 5 in a pharmaceutically effective amount to an individual other than a human suffering from sarcopenia.